89
Participants
Start Date
July 31, 2014
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
Part A: Placebo
Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
Part A: CR845 0.5 mcg/kg
Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Part A: CR845 1.0 mcg/kg
Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Part A: CR845 2.5 mcg/kg
Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
Part B: Placebo
Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
Part B: CR845 1.0 mcg/kg
Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
Trude Weishaupt Memorial Dialysis Center, Fresh Meadows
Winthrop University Hospital, Mineola
Brookview Hills Research Associates, LLC, Winston-Salem
US Renal Care, Aiken
Emory Dialysis Center at Northside, Atlanta
University of Florida College of Medicine Jacksonville, Jacksonville
Orlando Clinical Research Center, Orlando
Pines Clinical Research, Inc., Pembroke Pines
Vanderbilt University Medical Center, Nashville
Southeast Renal Research Institute, Chattanooga
US Renal Care, Pine Bluff
US Renal Care, Grand Prairie
US Renal Care, San Antonio
US Renal Care, Gallup
US Renal Care, Long Beach
Valley Renal Medical Group, Northridge
North American Research Institute, San Dimas
US Renal Care, Chula Vista
Nephrology Specialists Medical Group, Inc, Orange
Western New England Renal & Transplant Associates, PC, Springfield
Lead Sponsor
Cara Therapeutics, Inc.
INDUSTRY